Achilles Therapeutics
ACHL
ACHL was delisted on the 20th of March, 2025.
21 hedge funds and large institutions have $27.7M invested in Achilles Therapeutics in 2024 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 5 closing their positions.
12% more capital invested
Capital invested by funds: $24.8M → $27.7M (+$2.9M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
5% less funds holding
Funds holding: 22 → 21 (-1)
20% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 5
25% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BNP Paribas Financial Markets
Paris,
France
|
+$51.7K |
| 2 |
Two Sigma Investments
New York
|
+$41.6K |
| 3 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$27.6K |
| 4 |
Morgan Stanley
New York
|
+$17.8K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$16.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$93.7K |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
-$60.8K |
| 3 |
CCM
Corsair Capital Management
New York
|
-$20.4K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$12.7K |
| 5 |
BBA
Baader Bank Aktiengesellschaft
Unterschleissheim,
Germany
|
-$10.4K |
ACHL Hedge Fund Activity: Q4 2024 in Review
21 of the 7,593 institutional investors tracked by Wall St. Rank reported a position in Achilles Therapeutics (ACHL) for Q4 2024, worth a combined $27.7M — up 12% from $24.8M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of ACHL and 4 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 3 added.
The largest buyer was BNP Paribas Financial Markets, opening a new position worth an estimated $51.7K. The largest seller was Renaissance Technologies, cutting an estimated $93.7K.
- 21 institutional investors held Achilles Therapeutics (ACHL) as of Q4 2024, down from 22 in Q3 2024.
- Funds reported $27.7M of Achilles Therapeutics stock for Q4 2024, up 12% quarter-over-quarter.
- 4 funds opened new Achilles Therapeutics positions in Q4 2024 and 5 closed out, a net change of -1 holder.
- The largest Achilles Therapeutics buyer in Q4 2024 was BNP Paribas Financial Markets, an estimated $51.7K added.
- The largest Achilles Therapeutics seller in Q4 2024 was Renaissance Technologies, an estimated $93.7K sold.
Based on aggregated 13F filings for Q4 2024.